Trial Profile
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine; Idelalisib; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND
- Sponsors Acerta Pharma
- 29 Feb 2024 According to the BeiGene Media Release, a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA (zanubrutinib) versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials, presented at 28th Annual International Congress on Hematologic Malignancies in Miami from February 29 - March 3.
- 29 Feb 2024 Results published in the BeiGene Media Release
- 12 Dec 2023 Results of pooled analysis from CL001 , CL003 , CL006, CL007 and CL309 , presented at the 65th American Society of Hematology Annual Meeting and Exposition